The FDA has approved AbbVie’s Juvmo (tavapadon), the first selective D1/D5 dopamine agonist for Parkinson’s disease, as a once-daily tablet.
Existing dopamine agonists mainly target D2 and D3 receptors. AbbVie says Juvmo’s different mechanism may offer more flexibility for patients whose treatment is limited by side effects.
The approval at a glance
- Drug: Juvmo (tavapadon)
- Indication: Parkinson’s disease in adults
- Dosing: Once-daily tablet, with or without levodopa
- Strengths: 5mg, 10mg and 15mg, plus a titration pack
- US availability: Expected in October 2026
What the trials showed
The approval is based on AbbVie’s phase 3 TEMPO programme:
- Early Parkinson’s (TEMPO-1, without levodopa): Daily-living scores improved by 1.6 to 1.7 points at week 26, compared with a 0.9-point worsening on placebo.
- With levodopa (TEMPO-3): Patients with motor fluctuations gained 1.7 hours of “on” time without troublesome dyskinesia, versus 0.6 hours on placebo.
- Long term (TEMPO-4): At 85 weeks, 93% of patients taking Juvmo with levodopa had not increased their levodopa dose.
Safety
Most side effects were mild or moderate, including nausea, headache, dizziness and fatigue. Warnings include low blood pressure on standing, impulse-control problems such as compulsive gambling or shopping, hallucinations, and new or worsening dyskinesia.
Where it came from
Tavapadon came to AbbVie through its acquisition of Cerevel Therapeutics, agreed in 2023 for $8.7bn.
Why it matters
- A new mechanism. Juvmo is the first selective D1/D5 agonist approved for Parkinson’s.
- A large patient group. Parkinson’s is one of the most common neurodegenerative diseases, and many patients need alternatives to existing therapies.
- Payback on a big deal. The approval is a key return on the Cerevel acquisition.
What it means for the supply chain
As an oral, once-daily tablet, Juvmo will move through standard retail and specialty pharmacy channels. A launch this month means stocking decisions at wholesalers and pharmacies in the coming weeks, with titration packs adding packaging complexity.
The bottom line
Juvmo gives Parkinson’s patients a new type of dopamine agonist. Its uptake will depend on how doctors weigh the new mechanism against established treatments.
Frequently Asked Questions
What is Juvmo? Juvmo (tavapadon) is a once-daily tablet for Parkinson’s disease and the first selective D1/D5 dopamine agonist.
Can it be taken with levodopa? Yes, it can be taken with or without levodopa.
When will it be available? AbbVie expects US availability in October 2026.
What are the main side effects? Nausea, headache, dizziness and fatigue are common. Warnings include low blood pressure on standing, impulse-control problems and hallucinations.
Sources
| Source | Used for |
|---|---|
| AbbVie press release | Approval, indication, dosing, trial data, safety and availability |
| Life Science Daily News | Cerevel acquisition background |
Additional Resources
| Resource | What you’ll find |
|---|---|
| US Food and Drug Administration (FDA) | Prescribing information |
| Parkinson’s Foundation | Information on Parkinson’s disease and treatments |
| ClinicalTrials.gov | TEMPO trial records |
| AbbVie investor relations | Neuroscience portfolio updates |
Data note: Trial results are as reported by AbbVie from its own studies. Pricing was not disclosed.